Navigation Links
Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco

Company Also Announces Completion of Enrollment in U.S. Phase II Study of Nitazoxanide in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1

TAMPA, Fla., Oct. 28 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced the presentation of studies of nitazoxanide at the upcoming 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(R), and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL) in San Francisco, October 31 - November 4, 2008.

Nitazoxanide Abstracts

-- "Evaluation of a 4 Week Lead-In Phase with Nitazoxanide (NTZ) Prior

to Peginterferon (PEGIFN) Plus NTZ for Treatment of Chronic Hepatitis C:

Final Report," J. Rossignol et al., Sunday, November 2, 4:15 PM PST

(Oral Session IASL #87), and Tuesday, November 4, 8:00 AM - 12:30 PM

PST (AASLD Presidential Poster #1848)

-- "Potential Role for Nitazoxanide in Combination with STAT-C Agents

for the Inhibition of HCV Replication Without the Development of

Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session


-- "Nitazoxanide (NTZ) is an Inducer of eIF2a and PKR

phosphorylation," Elazar et al., Tuesday, November 4, 8:00 AM -

12:30 PM PST (Poster #1881)

STEALTH C-3 Fully Enrolled

In addition, Romark announced it has completed enrollment of patients into its U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C genotype 1 (STEALTH C-3). The STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C) study began enrollment in April 2008, and 112 patients were ultimately enrolled at 13 centers in the U.S. Data from a planned interim analysis is expected in early 2009.

A Phase II randomized, double-blind, placebo-controlled clinical trial, STEALTH C-3 is designed to evaluate the safety and efficacy of nitazoxanide in combination with peginterferon alfa-2a (Pegasys(R), Roche) and ribavirin (Copegus(R), Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1. The primary objective of this trial is to evaluate sustained virologic response (SVR) with a treatment regimen of 4 weeks of nitazoxanide lead-in therapy followed by 48 weeks of standard of care plus nitazoxanide versus 4 weeks of placebo lead-in followed by 48 weeks of standard of care and placebo.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood. A large majority of those infected do not show symptoms, but fatigue, abdominal pain and nausea can be common. The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. According to the Centers for Disease Control, HCV affects an estimated 4.1 million Americans.

About Romark Laboratories

Romark Laboratories (, a privately held biopharmaceutical company, has discovered and developed a new class of small molecule antivirals known as thiazolides. The Company is developing nitazoxanide, the first of the thiazolide class, for the treatment of chronic hepatitis C, and is developing other new thiazolides for treating viral diseases including chronic hepatitis B. Alinia(R) (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of infections caused by Cryptosporidium or Giardia.

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
4. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
5. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
6. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
7. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
9. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
10. AIT Laboratories Expands Pharma Services
11. TriMix Laboratories Announces New Partnership With American Pharmacy Solutions
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):